Celgene Partners with Abide to Bring Cannabis-like Treatment for MS into Further Clinical Tests

Patricia Silva, PhD avatar

by Patricia Silva, PhD |

Share this article:

Share article via email
cannabis and neurlogical diseases

Abide TherapeuticsĀ announced that Celgene has opted to obtain theĀ rights, outside of the United States, to ABX-1431, Abideā€™s endocannabinoid system modulator being developed to treat neurological diseases, including multiple sclerosis (MS), by reproducing within the body the physical benefits (minus the psychotropic effects) of cannabis.

ABX-1431 is an oral, selective, small molecule inhibitor of monoacylglycerol lipase (MGLL) ā€” an enzyme that catalyzes the breakdown of the endogenous cannabinoid, 2-arachidonoylglycerol (2-AG) and serves the major regulator of its levels. In turn, 2-AG isĀ thoughtĀ to regulate neurotransmitter balance and inflammation. Immune attacks, like those that characterize MS, lead toĀ neurotransmitter imbalance.

The cannabinoid 2-AG binds toĀ the cannabinoid receptors CB1 and CB2 ā€” the molecular targets of the psychoactive component of cannabis: delta-9 tetrahydrocannabinol or THC. CB1 is the primary cannabinoid receptor in the nervous system, and its activation accounts for most of the neurobehavioralĀ effects of THC. CB2 is found primarily on immune cells and mediates the immunosuppressive effects of cannabinoids.

Direct activation of cannabinoid receptors by medicinal cannabis is thought to offerĀ therapeutic benefits toĀ conditions like spasticity, pain, disrupted sleep, nausea, and poor appetite. ABX-1431 has the potential to produce similar therapeutic benefits.

Celgene will pay $20 million to Abide for these rights, part of an agreement between the two companies reached in 2014, and be in charge of development costs of allĀ indications from Phase 2 clinical trials onward. Abide will retain U.S. rights and will leadĀ Phase 1b studies.

ā€œ[W]e plan to perform a number of Phase 1b studies to evaluate the therapeutic potential of what appear to be cannabinoid-sensitive diseases. We plan to study neuromyelitis optica (NMO) and movement disorders as follow-on indications,ā€ Alan Ezekowitz, MDChB, DPhil, Abide Therapeuticsā€™ chief executive officer and president, said in a press release.

The company announced that dosing had finished in a Phase 1a studyĀ of ABX-1431 in healthy subjects and results found the drug to be well-tolerated with no serious adverse reactions.

“We are delighted with the rapid progress that the Abide team has made in bringing forward ABX-1431. We look forward to evaluating the therapeutic potential of this exciting molecule in MS. We also recognize that this mechanism has broad therapeutic potential for a range of neurological diseases,ā€ saidĀ Rupert Vessey, BMBCh, DPhil, Celgene Corporationā€™s president of research and early development.